We developed a clinical score to monitor tuberculosis patients in treatment and to assess clinical outcome. We used the WHO clinical manual to choose signs and symptoms, including cough, haemoptysis, dyspnoea, chest pain, night sweating, anaemia, tachycardia, lung-auscultation finding, fever, low body-mass index, low mid-upper arm circumference giving patients a TBscore from 0 to 13. We validated the score with data from a cohort of 698 TB patients, assessing sensitivity to change and ability to predict mortality. The TBscore declined for 96% of the surviving patients from initiation to end of treatment, and declined with a similar pattern in HIV-infected and HIV-uninfected patients, as well as in smear negative and smear positive patients. The risk of dying during treatment increased with higher TBscore at inclusion. For patients with a TBscore of >8 at inclusion, mortality during the 8 months treatment was 21% (45/218) versus 11% (55/480) for TBscore <8 (p< 0.001). TBscore assessed at end of treatment also strongly predicted subsequent mortality. The TBscore is a simple and low-cost tool for clinical monitoring of tuberculosis patients in low-resource settings and may be used to predict mortality risk. Low TBscore or fall in TBscore at treatment completion may be used as a measure of improvement.

中文翻译：

---

TB评分：资源贫乏地区的结核病患者的体征和症状具有预测价值，可用于评估临床病程。

我们制定了临床评分，以监测治疗中的结核病患者并评估临床结局。我们使用WHO的临床手册来选择体征和症状，包括咳嗽，咯血，呼吸困难，胸痛，盗汗，贫血，心动过速，肺部听诊，发烧，低体质指数，上臂中低周长给患者TB评分从0到13。我们使用698例TB患者队列的数据验证了评分，评估了变化的敏感性和预测死亡率的能力。从开始治疗到结束治疗期间，尚存的患者中TBscore下降了96％，并且在HIV感染者和HIV未感染者以及涂片阴性和涂片阳性患者中，TBscore的下降趋势相似。纳入时，TBscore越高，治疗期间死亡的风险越大。对于入选时TBscore大于8的患者，治疗8个月内的死亡率为21％（45/218），而TBscore <8则为11％（55/480）（p <0.001）。治疗结束时评估的TBscore也强烈预测了随后的死亡率。TBscore是用于在资源贫乏地区进行结核病患者临床监测的一种简单且低成本的工具，可用于预测死亡风险。治疗结束时，TBscore较低或TBscore下降可作为改善的指标。TBscore是用于在资源贫乏地区进行结核病患者临床监测的一种简单且低成本的工具，可用于预测死亡风险。治疗结束时，TBscore较低或TBscore下降可作为改善的指标。TBscore是用于在资源贫乏地区进行结核病患者临床监测的一种简单且低成本的工具，可用于预测死亡风险。治疗结束时，TBscore较低或TBscore下降可作为改善的指标。